CVI Quarterly

Dr Kenneth Mahaffey former Pro-fessor of Medicine at Duke Universi-ty and Faculty Associate Director of the Duke Clinical Research Institute (DCRI) has joined the Stanford De-partment of Medicine as the Vice Chair of Medicine for Clinical Research as of Aug 1 2013

Dr Mahaffey received a BS in Chemistry from Stanford followed by his MD from the University of Wash-ington and residency training at the University of Arizona Health Sciences Center He completed a cardiology fel-lowship at Duke including research training in the Duke Databank for Cardiovascular Disease After joining the faculty at Duke he rose over the next 17 years to Professor of Medicine and a recognized international leader in the design and conduct of large-scale cardiovascular trials At the

DCRI he led the development of the field of cardiovascular clinical event detection and adjudication as critical methods in the conduct of random-ized clinical trials

He has led efforts at the US FDA to standardize definitions for cardiac events in clinical trials while leading a multidisciplinary group at DCRI re-sponsible for coordinating event de-tection and adjudication in clinical studies across multiple disciplines including oncology hepatology re-nal disease rheumatology and car-diovascular disease among others He has mentored and trained a large group of international clinical re-search fellows in research methods

Over the last ten years Dr Mahaffey has served as Chair of one of the Duke IRBs while helping to lead efforts to streamline and improve the IRB appli-

cation and review process He main-tains active research collaborations with dozens of clinical researchers across the US and the globe z

For more httptinyurlcomkld-7pqo

The Stanford Cardiovascular Institute (CVI) is pleased to announce the appointment of Philip Sager MD FACC FAHA

FHRS as CVI Consulting Professor effec-tive July 15 2013 Dr Sager performed his undergraduate work at MIT and at-tended medical school and completed his medical residency cardiology and electrophysiology fellowships at Yale University After a long academic career at UCLA where his research focused on physiologic and drug-induced alter-

ations in cardiac repolarization and he was a tenured faculty member he moved to the pharmaceutical industry

He played key leadership roles in the development of Zetia

Philip Sager MD Joins CVI

Summer 2013Cardiovascular Institute

New Vice Chair of Medicine for Clinical Research

In This IssueNew Vice Chair for Clinical Research page 1Philip Sager MD Joins CVI page 1-2Duchenne Muscular Dystrophy page 2 Using 3D Printing to Model Organs page 3Reversing Pulmonary Hypertension page 3-4Hormone Therapy No Cognitive Effects page 4New Collagen Patch Aids Heart Repair page 5US News and World Reports page 5Familial Hypercholesterolemia Summit page 6PAD Stem-Cell Study page 6CVI NewsBeats page 7-8CVI Travel Awards page 8Recruiting AssistantAssociateFull Professor page 8CVI Publications page 9-11Upcoming Grants Awards Page 12CVI Frontiers Upcoming Meetings Page 13CVI Leadership Page 14

1

Kenneth Mahaffey MD

Philip Sager

SAGER continues on p 2

CVI Quarterly is a newsletter that showcases the academic and re-search activities of the Stanford Cardiovascular Institutersquos members

CVI Quarterly Editorial Team

265 Campus Drive G1120 MC-5454 Stanford CA 94305Phone 650-725-7964 httpcvistanfordedu

Articles marked with z reprinted with permission fromStanfordrsquos Office of Communication amp Public Affairs

Articles marked with v reprinted with permission from Stanford Hospital amp Clinics Office of Communications

SAGER from p 1

2

Janet Kalesnikoff David L M Preston

Newsletter EditorCVI Associate Director

Newsletter Copy-editorCVI Program Manger

jkalesnistanfordedu prestonstanfordedu

Vytorin Crestor Letairis Brilinta and the Corus CAD diagnostic test He has deep global expertise in the CV safety of drugs and was the ICH Expert Working Group PhRMA Topic Leader for the QT interval reg-ulatory guidance (ICH E14) and is Chair of the Sci-entific Programs Committee and a member of the Executive Committee of the Cardiac Safety Research Consortium

Dr Sager is a voting member of the FDA Cardio-Re-nal Advisory Committee and is actively involved in developing collaborations between regulators in-dustry and academia on new approaches to inno-vative drug development as well as CV safety assess-ment of pharmaceuticals and devices He also has an interest in mobile health Dr Sager will partici-pate in collaborative research and teaching z

For more httptinyurlcomlmwcnbf

BY KRISTA CONGER

Duchenne muscular dystrophy is a heart-breaking genetic disorder that usually kills patients in their teens and twenties Although the most prominent symptom is a gradual progressive mus-cle weakness most patients die from respiratory or cardiac failure Itrsquos been difficult to determine exactly how the heart is damaged though since mice with the same genetic mutation display only mild symptoms

This lack of an adequate animal mod-el has hampered research on the disor-der for decades But now researchers from the laboratory of Helen Blau PhD the Donald E and Delia B Baxter Pro-fessor have developed a new strain of mice that more-closely mimics the course of the disease in humans

The investigators found that the rea-son humans suffer more serious symp-toms than mice has to do with the length of the protective caps called telo-meres on the ends of chromosomes Mice have telomeres about 40 kilobas-es in length while human telomeres

range from around 5 to 15 kilobases (a kilobase is 1000 nucleotides) When the investigators introduced a second mutation in the animals that reduced telomere length to more closely match that of humans the animals began to display the typical symptoms of the disease including progressive muscle weakness enlarged hearts and signifi-cantly shortened life spans

Humans with Duchenne muscular dystrophy (and mice serving as models for the condition) bear a mutation in the gene that encodes for the dystrophin protein which supports and protects muscle fibers during contraction When the researchers closely examined the heart muscle cells of the animals in the study they found that their heart mus-cle cells accumulate damage due to ox-idative stress as they maintained their rhythmic contractions in the absence of the dystrophin protein

The researchers found that treating affected mice with antioxidants early in the course of their disease delayed the onset of heart failure and increased the animalsrsquo life span

The study reveals an intriguing link between telomere length and cardiac function But itrsquos real strength lies in the ability to advance our understanding of Duchenne muscular dystrophy and speed the development of new treatments z

For more httptinyurlcommn-sy37s and httptinyurlcomknhwl9e

Foteini Mourkioti (left) and Helen Blau (right)

Photo Norbert von der Groeben

Duchenne Muscular Dystrophy Mystery Solved

Link to full article inNature Cell Biology

httpwwwncbinlmnihgovpubmed23831727

3

BY CAROLYN JOHNSON AND TIM DIDION (KGO-TV ABC7)

Surgeons have made huge strides in treating the human heart Now researchers at Stanford University are using a new technique that could soon make those sur-geries even more precise by starting with an ex-act replica of the patientrsquos heart

ldquoTo be able to have a structure of the heart in front us and be able to hold it in our hands and to be able to test the new devices that wersquore de-veloping is really a miraclerdquo says Dr Paul Wang

The key to creating these 3D models is a state of the art printer that looks something like a supersized microwave oven Wang believes the combination of software and engineering that produces a nearly perfect copy of a patientrsquos heart could revolutionize medicine

First CT scans capture multiple views of the heart as a series of slices And the next step after that is to take this data and select out what data we want to make our 3D model out ofrdquo says research fellow Jeff Caves PhD

Caves says that engineers ultimately layer the CT images and their corresponding measurements onto sophisticat-ed CAD software similar to what architects use to create blueprints for buildings slowly translating them into an accurate computer model to guide the 3D printer

ldquoAll these angles represent surfaces and itrsquos full 3D at this pointrdquo he explains

Using reams of plastic the 3D printer then reproduces the heart in a process that takes several hours The results from the point of view of a cardiolo-gist are stunning

ldquoItrsquos revolutionaryrdquo says Wang ldquoOne can leave the settings overnight and come back the next day and have a completed heart You can see the exceptional detail the structures that hold the valves in placerdquo

Wang says the models are so accurate that surgeons could potentially scale and fit devic-

es ranging from catheters to coronary stents to the pre-cise dimensions of an individualrsquos heart The technology could allow doctors to test different surgical strategies in advance before a patient ever enters the operating room

There is also intense research underway across the country using 3D printing technology combined with living cells and other biological material The goal is to someday construct functioning human organs z

For more httptinyurlcomq7kabh5 and ABC site httptinyurlcomocm3v8s(Reprinted with permission Copyright copy2013 KGO-ABC7 News TVDT All Rights Reserved)

Paul Wang

Using 3D Printing to Model Organs

BY TRACIE WHITE

Mark Nicolls and his colleagues dis-covered that blocking a pathway that causes inflammation could reverse a deadly condition known as pulmo-nary hypertension in rats

Pulmonary hypertension a deadly form of high blood pressure that de-velops in the lungs may be caused by an inflammation-producing mo-lecular pathway that damages the in-ner lining of blood vessels according to a new study by researchers at the Stanford University School of Medi-cine

The results suggest that using med-

ications to block this pathway could lead to the first-known cure for the disease apart from lung transplan-tation The new research could also lead to a better understanding of oth-er diseases involving inflammation of blood vessels such as coronary artery disease said Mark Nicolls MD senior author of the study and division chief of pulmonary and critical care medi-cine at Stanford as well as a staff phy-sician at the Veterans Affairs Palo Alto Health Care System

ldquoWe believe that targeting inflam-mation is an exciting approach to augment current treatments for pul-monary hypertension because it may

reverse the underlying cause of the diseaserdquo said Nicolls who is also di-rector of the Lung Immunology Pro-gram and an associate professor of

Reversing Pulmonary Hypertension

PULMONARY continues on p 4

Mark NicollsPhoto Steve Fisch

4

medicine ldquoWe believe this is going to be an approach that helps a large number of patientsrdquo

Pulmonary hypertension while rare usually strikes young and middle-aged women leaving them short of breath and often unable to complete simple daily tasks The condition can be fatal The risk is higher for people with certain autoimmune diseases (such as scleroderma or lupus) HIV congenital heart disease or liver disease

About 100000 people in the United States and Europe have been diagnosed with pulmonary hypertension but many others are believed to go undiagnosed because the main symptom shortness of breath is nonspecific Until the 1990s there were no treatments except lung trans-plantation which has varying degrees of success

What is known about the disease is that the narrowing of blood vessels in the lungs is caused by a mysterious proliferation of the smooth muscle cells that ring those vessels As the vessel walls thicken they become increas-ingly occluded choking off blood flow

The current treatment for patients with pulmonary hy-pertension is vasodilators drugs that cause smooth mus-cle cells to relax permitting more blood to flow through the diseased vessels These drugs help to extend survival and relieve some symptoms but they donrsquot provide a cure

ldquoCurrent approved therapies for pulmonary hyper-tension have focused on dilating blood vessels without special attention being paid to the inflammation that is

frequently seen around blood vesselsrdquo Nicolls said ldquoWe were interested in finding out how inflammation contrib-utes to the diseaserdquo

In laboratory experiments researchers removed inflam-mation-producing cells called macrophages from the lung tissue of rats dying of pulmonary hypertension and put the cells in cultures with healthy rat endothelial cells

ldquoWe were shocked to find that half of the endothelial cells were dead within 24 hoursrdquo Nicolls said ldquoThat totally surprised usrdquo

In subsequent lab experiments researchers found that if they blocked the molecular pathway triggered by the mac-rophages the endothelial cells didnrsquot die Researchers con-ducted similar experiments in human tissue taken from the diseased lungs of patients The results were similar ldquoThe same pathways were at play in the human lungsrdquo Nicolls said

In experiments in live rats with induced pulmonary hy-pertension the disease was reversed when researchers blocked the inflammation-producing pathway

ldquoIt was dramaticrdquo Nicolls said ldquoWe could start the drug as late as three weeks when animals were breathing hard and walking slowly and the disease reversedrdquo z

For more httptinyurlcompnppnsj

PULMONARY from p 3

BY MICHELLE BRANDT

Some news affecting post-menopausal women who take hormone therapy In a study involving 1326 women who started conjugated equine estrogen-based hormone therapy when they were between 50 and 55 years old the treatment was not associ-ated with any sustained risk or benefit to brain health

Much has been written about this topic dat-ing back about 10 years ago to the release of the Womenrsquos Health Initiative Memory Study which linked the same type of therapy to cognitive de-cline and dementia in older (65 years+) postmenopausal women This study however involved younger women whose cognitive function was assessed an average of 7 years after their participation in the trial was over

ldquoThere was essentially no overall difference in cognitive

function between women who had been prescribed an av-erage of 7 years of hormone therapy compared to women who had been prescribed placebordquo the researchers report

The research may be reassuring to women who take or are consider taking hormone ther-apy in their 50s And the findings also as co-au-thor Marcia Stefanick PhD with the Stanford Prevention Research Center points out fail to ldquosupport the lsquowindow of opportunityrsquo hypothe-sis which suggests that women closer to meno-pause will benefit with respect to cognitive func-tion as they agerdquo z

For more httptinyurlcomoayj4dp

Hormone Therapy No Cognitive Effects

Marcia Stefanick

Link to full article inJAMA Internal Medicine

httpwwwncbinlmnihgovpubmed23797469

Link to full article inScience Translational Medicine

httpwwwncbinlmnihgovpubmed23986401

5

BY JAMES LARKIN

Stanford Hospital amp Clinics has been ranked one of the best hospitals for 2013-14 by US News amp World Report in 13 out of 16 medical specialties The magazine also ranked Stan-ford one of the top two hospitals in the state of California and the best in the metro area

The hospital also earned national rank-

ings in three additional specialties over last year Stanford was ranked among the na-tionrsquos very best hospitals in cancer cardiolo-gyheart surgery ear nose amp throat gastroen-terology geriatrics gynecology nephrology neurologyneurosurgery orthopaedics psy-chiatry pulmonology rheumatology and urology v

For more httptinyurlcomnaptew3

US News amp World Reports Ranks SHC Highly

BY LOUIS BERGERON

When heart cells die from lack of blood flow during a heart attack replacing those dead cells is vital to the heart musclersquos recovery But muscle tissue in the adult human heart has a limited capacity to heal which has spurred researchers to try to give the healing process a boost

Researchers at the Stanford University School of Medicine and Lucile Packard Chil-drenrsquos Hospital have developed a patch com-posed of structurally modified collagen that can be grafted onto damaged heart tissue Their studies in mice have demonstrated that the patch not only speeds generation of new cells and blood vessels in the damaged area it also limits the degree of tissue damage result-ing from the original trauma

The key according to Pilar Ruiz-Lozano PhD associate professor of pediatrics is that the patch doesnrsquot seek to replace the dead heart-muscle cells Instead it replaces the epi-cardium the outer layer of heart tissue which is not muscle tissue but which protects and supports the heart muscle or myocardium

ldquoThis synthetic tissue has the mechanical properties of the embryonic epicardiumrdquo said Ruiz-Lozano who is the senior author of a study that describes the researchersrsquo findings

Embryonic epicardium is significantly more flexible than adult epicardium but more rigid and structured than ex-isting materials making it more conducive to growth of new tissue ldquoWe paid tremendous attention to the phys-ical properties of the materials and how their elasticity could modify the function of the heartrdquo Ruiz-Lozano said

The epicardium mdash or its artificial replacement mdash has to

allow the cell migration and proliferation needed to rebuild damaged tissue as well as be sufficiently permeable to al-low nutrients and cellular waste to pass through the net-work of blood vessels that weaves through it The mesh-like

structure of collagen fibers in the patch has those attributes serving to support and guide new growth Because the patch is made of acellular collagen meaning it contains no cells recipient animals do not need to be immunosuppressed to avoid rejection With time the collagen gets absorbed into the organ

In addition to helping heart tissue regener-ate the patch could be used as a delivery sys-tem for getting medications or stem cells into a patient Ruiz-Lozano said

Daniel Bernstein MD professor of pediatric cardiology and a co-author of the paper said the potential of the patch as a delivery system could make it useful in treating children with heart problems

ldquoFor pediatric patients with congenital heart disease or who have heart damage from a vi-

ral infection or other heart injury we could use this to in-troduce growth factors directly to the heart in a way that would persist for a long period of timerdquo he said

Ruiz-Lozano and her colleagues are already at work on studies to explore the use of the patch as a delivery sys-tem along with conducting studies of how the patch will perform in larger animals

For more httptinyurlcommk4swff

z

Pilar Ruiz-Lozano

New Collagen Patch Aids Heart Repair

Link to full article inBiomaterials

httpwwwncbinlmnihgovpubmed23992980

Daniel Bernstein

46

BY SARA WYKES

An international summit this month focuses on an inher-ited but highly underdiagnosed condition that causes pre-mature cardiovascular disease and will feature two promi-nent Stanford medicine community members

Stanford instructor Josh Knowles MD PhD is the chief medical officer of the Familial Hyper-cholesterolemia Foundation the group hosting the summit and the first patient advocacy orga-nization to represent people with the condition Knowles is also an attending physician with the Familial Hypercholesterolemia Clinic at the Stan-ford Center for Inherited Cardiovascular Disease

Ted Tussing director of the Stanford Hospital Corporate Partners program serves on the FH Foundationrsquos board of directors He was diag-nosed with FH at age 13 and both his sons also have it

ldquoDr Knowlesrsquo leadership and involvement with the FH Foundation reflects not only Stanfordrsquos strengths but also the future of medical care--leveraging the best synthesis of basic science discovery big data care delivery and wellness strategiesrdquo Tussing said

While cholesterol is a natural and necessary part of the bodyrsquos chemistry genetic mutations can alter how it is eliminated from the bloodstream FH affects cholesterol processing from birth affecting the cardiovascular system

so pervasively that over the course of a lifetime the toll on arteries means that men with FH have a 50 percent chance of having a heart attack by age 50 Women with FH have a 30 percent chance of heart attack by age 60

Though the condition is common and affects over 600000 in the US the condition is diagnosed in less than 10 percent of those who suffer from it The need for heightened awareness is clear FH accounts for 20 percent of heart attacks in people less than 45 years old

FH is a genetic condition If just one parent has the condition children have a 50 percent chance of inheriting it The familial nature and the serious health consequences of FH have placed it on the Centers for Disease Control and Preventionrsquos Tier 1 list of conditions for which screening is recom-

mended in particular at an early age for children of adults diagnosed with FH

The Familial Hypercholesterolemia Summit is an effort to bring together scientists clinicians public health officials interested companies and individuals with FH to find inno-vative solutions The Summit will be held on Sept 18-19 in Annapolis Maryland ldquoThe main goal will be to develop ac-tionable recommendations that will embed FH in a strong public health movementrdquo Knowles said v

For more httpwwwthefhfoundationorg and httptinyurlcomq4bn8oo

BY TRACIE WHITE

The Stanford University School of Medicine is recruiting people with pain from peripheral arterial disease (PAD) for a clinical trial to determine whether injections of adult stem cells into leg muscles help treat the condition

Stanford is one of seven sites participating in the randomized study which will evaluate leg blood flow and symptoms of PAD in two groups of patients who suffer leg pain while exercising as a result of the condition those treated with their own stem cells taken from bone marrow and those treated with placebo All patients will be followed for one year The phase-1phase-2 study has begun recruitment and is expected to enroll 10 patients at Stanford

PAD occurs when arteries in the arms and legs become nar-rowed by plaque About 1 million to 3 million Americans suffer

from a form of the disease that causes pain while exercising because muscles are not getting enough oxygenated blood

For this study stem cells will be taken from the bone marrow of all participants Those randomized to the treat-ment group will have their stem cells injected into the diseased area of the calf and lower thigh mus-cles to see if it improves blood flow or walking time or both (The control group will receive a placebo injection) Bone marrow contains special stem cells that may promote blood vessel growth prevent cell death and transform themselves into new tissues

The study is funded by the NHLBI of the Nation-al Institutes of Health (grant UM1HL12026) The

principal investigator for the Stanford portion of the trial is Phillip Yang MD associate professor of cardiovascular medicine To enroll contact Fouzia Khan at (650) 736-1410 or fouziakstanfordedu z

For more httptinyurlcomkc22ty6

Familial Hypercholesterolemia Summit

PAD Stem-Cell Study Seeks Participants

Joshua Knowles

Phillip Yang

CVI NewsBeats

Sonja Schrepfer MD PhD received the Leducq Transatlantic Career De-velopment Award for her work in-vestigating mechanisms of immune tolerance which might someday be used to avoid the unwanted immune reactions provoked by the use of em-bryonic stem cells as a treatment for heart failure For more httptinyurlcomkq9lkhn

Michael Snyder PhD Director of the Stanford Center for Genomics and Personalized Medicine was featured in a Palo Alto Weekly cov-er story about research that could translate genetic discoveries into widespread personalized medicine For more httptinyurlcomlath-jua httptinyurlcoml8l8lxp and httptinyurlcomknqrzj3

Atul Butte MD PhD Chief of Sys-tems Medicine and Associate Pro-fessor of Pediatrics and of Genet-ics was recognized by The White House as an open science Cham-pion of Change He was among 13 entrepreneurs academics and researchers honored June 20 at the White House For more httptinyurlcomk59jv84

Julia Ransohoff CVI-affiliated Stan-ford medical student and Bruno Huber PhD have shown that a dual agent approach of CTL4Ig and an-ti-LFA1 is more effective than predni-sone and cyclosporine A for prevent-ing rejection of human ESC-derived endothelial cells in animal model of myocardial infarction For more httptinyurlcommdhu39a and httptinyurlcomm6nv7zt

Nazish Sayed MD PhD Former CVI T32 fellow (July 2010 - June 2013) has been hired as a Scien-tist in the Dept of Cardiovascular Sciences at Methodist Hospital Research Institute Houston TX as of July 1 When at Stanford his Mentors included John Cooke MD PhD Edward Mocarski PhD and Karla Kierkegaard PhD

Andrew Connolly MD PhD As-sociate Professor of Pathology received the Kaiser Foundation Award for Excellence in Preclini-cal Teaching whose recipients are chosen by students in preclinical medicine For more httptinyurlcomk4zdzov

Ngan Huang PhD was appointed Assistant Professor of Cardiotho-racic Surgery effective May 1 Her lab aims to understand the chem-ical and mechanical interactions between extracellular matrix pro-teins and pluripotent stem cells that regulate vascular and myo-genic differentiation

Sean Wu MD PhD has been named an Endowed Faculty Schol-ar of the Child Health Research Institute and the Lucile Packard Foundation for Childrenrsquos Health at Stanford The newest class of Endowed Faculty Scholars are ap-pointed to 5-year terms beginning Sept 1 For more httptinyurlcomk89o2po

7

CVI NewsBeatsTim Assimes MD PhD (left) and Philip Tsao PhD (right)received one of only three NHLBI contracts awarded in response to a Broad Agency An-nouncement for their project ldquoIntegrative genomics and risk of CHD and related phenotype in the Womenrsquos Health Initiative (WHI)rdquo Other PIs in-clude Devin Absher (Hudson Alpha Institute of Biotechnology) and Steve Horvath (UCLA) The study will apply genomic technologies on over 2000 WHI participants to identify circulating miRNA and DNA methylation pat-terns associated with coronary heart disease Detailed study objectives and more can be found at httptinyurlcomm9lzkom

Ivan Carcamo-Oribe (Josh Knowles Lab)Abstract Modeling Insulin Resistance Through iPSC Technology Meeting International Society for Stem Cell Research

Gadryn Higgs amp Alexandre Ribeiro (Beth Pruitt Lab)Abstract Inducing Variations in the Shortening of Single Cardiomyo-cytes with Localized Mechanical Stimulation Meeting International Conference on Microtechnologies in Medicine and Biology

Clint L Miller (Thomas Quertermous Lab)Abstract Disease-relevant pathways modulate a cis-regulatory el-ement at the TCF21 coronary heart disease locus Meeting Gordon Research Conference on Human Genetics and Genomics

Nils P Nickel (Marlene Rabinovitch Lab)Abstract The Elastase Inhibitor Elafin Restores Endothelial Cell Ho-meostasis In Pulmonary Arterial Hypertension And Attenuates Vascu-lar Remodeling In The SugenHypoxia Rat Model Meeting American Thoracic Society International Conference

Stephen Pan (Euan Ashley Lab)Abstract Cardiac Structural and Sarcomere Genes Associated with Cardiomyopathy Exhibit Marked Intolerance of Genetic Variation Meeting American Heart Association Scientific Sessions

Chirag J Patel (John PA Ioannidis Lab)Abstract Environment-wide Association Studies to Connect Multiple Personal Exposures to Health Meeting International Society for Ex-posure Sciences

Julia D Ransohoff (Joseph Wu Lab)Abstract Blockade of Costimulatory Molecule Signaling Promotes Survival of Human Embryonic Stem Cell-Derived Endothelial Cells by Inducing T Cell Immunoglobulin 3 Upregulation and Improves Cardiac Function Meeting International Society for Stem Cell Re-search

Vahid Serpooshan (Pilar Ruiz-Lozano Lab)Abstract Engineered Epicardium Activates Cardiac Regeneration Meeting Weinstein Cardiovascular Development Conference

Joshua M Spin (Philip Tsao Lab)Abstract MicroRNA-24 Controls Macrophage Survival in Murine Abdominal Aortic Aneurysm via Chi3l1 Meeting Arteriosclerosis Thrombosis and Vascular Biology Scientific Sessions

Ke Yuan (Vinicio de Jesus Perez Lab)Abstract Impaired Pulmonary Angiogenesis in IPAH Is Linked To Abnormal Pericyte Function And Reduced Endothelial-Pericyte In-teractions Meeting American Thoracic Society International Con-ference

Inaugural CVI Postdoctoral Travel Award Receipients

Application Deadline Thursday October 03 2013 The Stanford Cardiovascular Institute and the Division of Cardiovas-cular Medicine seek to jointly recruit a basic science researcher with an interest in the fundamental molecular and cellular basis of cardio-vascular diseaseThe applicant will have MD PhD or MD PhD degrees and will be appointed in the Medical Center Line or University Tenure Line Fac-ulty rank will be determined by the qualifications and experience of the successful candidate Preference will be given to researchers who are able to apply new and innovative approaches to the investigation of the risk for cardiovascular disease including the use of novel ani-mal models and the use of modern human and molecular genetics ap-proaches The ideal candidate will have completed rigorous training or have acquired applied experience in one or more related areas of translational research such as epidemiology clinical trials physiolo-gy cellular and molecular biology and human genetics The applicant will be expected to develop an independently funded research effort focused in this area and to help with teaching activities in the Division and the Department of Medicine Appropriate resources will be made available to help the applicant develop their research program It is highly desirable that the applicant have an MD degree be trained in cardiology and spend some time contributing to the patient care mis-sion of the Division but exceptional PhD applicants will also be con-sidered Stanford University is an equal opportunity employer and is committed to increasing the diversity of its faculty It welcomes nom-inations of and applications from women and members of minority groups as well as others who would bring additional dimensions to the universityrsquos research teaching and clinical missions Rank and sal-ary will be commensurate with qualifications and experienceThe predominant criterion for appointment in the University Tenure Line is a major commitment to research and teaching The major crite-ria for appointment for faculty in the Medical Center Line shall be excel-lence in the overall mix of clinical care clinical teaching scholarly activ-ity that advances clinical medicine and institutional service appropriate to the programmatic need the individual is expected to fulfillApplicants should send a copy of their curriculum vitae a brief letter outlining their interests and three reference letters either electroni-cally to marishasmithstanfordedu or via regular mail to

Tom Quertermous MDSearch Committee Chair co Marisha Smith1070 Arastradero Rd Suite 220Palo Alto CA 94304-5850

Stanford University is an equal opportunity employer and is committed to increasing the diversity of its faculty It welcomes nominations off and applications from women and

members of minority groups as well as others who would bring additional dimensions to the Universityrsquos research teaching and clinical missions

Now RecruitingAssistantAssociateFull Professor Dept of MedicineStanford University

8

CVI PublicationsJune 129 publications

Genetic variants associated with warfarin dose in Afri-can-American individuals a genome-wide association study Perera MA Cavallari LH Limdi NA [+35 authors] Altman RB Klein TE Nakamura Y Johnson JA Lancet 2013 Jun 4 [Epub ahead of print]Molecular regulation of stem cell quiescence Cheung TH Rando TA Nat Rev Mol Cell Biol 14(6)329-40Stem cell isolation Differential stickiness Abilez OJ Wu JCNat Mater 12(6)474-6Meta-analyses of hydroxyethyl starch for volume resuscitation Ioannidis JP JAMA 309(21)2209Genome-wide profiling of human cap-independent trans-lation-enhancing elements Wellensiek BP Larsen AC Ste-phens B Kukurba K Waern K Briones N Liu L Snyder M Jacobs BL Kumar S Chaput JC Nat Methods 2013 Jun 16 [Epub ahead of print]Risk-Standardizing Survival for In-Hospital Cardiac Arrest to Facilitate Hospital Comparisons Chan PS Berg RA Sper-tus JA Schwamm LH Bhatt DL Fonarow GC Heidenreich PA Nallamothu BK Tang F Merchant RM J Am Coll Cardi-ol 2013 Jun 12 [Epub ahead of print]Sorting Inactivated Cells Using Cell-Imprinted Polymer Thin Films Ren K Banaei N Zare RN ACS Nano 2013 Jun 5 [Epub ahead of print]Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseasesChurko JM Mantalas GL Snyder MP Wu JC Circ Res 112(12)1613-23Long-Term Effects on Cognitive Function of Postmenopaus-al Hormone Therapy Prescribed to Women Aged 50 to 55 YearsEspeland MA Shumaker SA Leng I Manson JE Brown CM Leblanc ES Vaughan L Robinson J Rapp SR Goveas JS Lane D Wactawski-Wende J Stefanick ML Li W Resnick SM for the WHIMSY Study Group JAMA Intern Med 2013 Jun 241-8Assessing research results in the medical literature trust but verify Califf RM McCall J Harrington RA JAMA Intern Med 173(12)1053-5Plasmid-Encoded Proinsulin Preserves C-Peptide While Spe-cifically Reducing Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes Roep BO Solvason N Gottlieb PA Abreu JR Harrison LC Eisenbarth GS Yu L Leviten M Hagopian WA Buse JB von Herrath M Quan J King RS Robinson WH Utz PJ Garren H BHT-3021 Investigators Steinman L Sci Transl Med 2013 Jun 26 5(191)

The role of ligands on the equilibria between function-al States of a g protein-coupled receptor Kim TH Chung KY Manglik A Hansen AL Dror RO Mildorf TJ Shaw DE Kobilka BK Prosser RS J Am Chem Soc 2013 Jun 26 135(25)9465-74Subepicardial endothelial cells invade the embryonic ventri-cle wall to form coronary arteries Tian X Hu T Zhang H He L Huang X Liu Q Yu W He L Yang Z Zhang Z Zhong TP Yang X Yang Z Yan Y Baldini A Sun Y Lu J Schwartz RJ Evans SM Gittenberger-de Groot AC Red-Horse K Zhou BCell Res 2013 Jun 25 [Epub ahead of print]Molecular consequences of the R453C hypertrophic car-diomyopathy mutation on human β-cardiac myosin motor function Sommese RF Sung J Nag S Sutton S Deacon JC Choe E Leinwand LA Ruppel K Spudich JA Proc Natl Acad Sci USA 2013 Jun 24 [Epub ahead of print]Ethnic Differences in the Relationship Between Insulin Sen-sitivity and Insulin Response A systematic review and me-ta-analysis Kodama K Tojjar D Yamada S Toda K Patel CJ Butte AJ Diabetes Care 2013 Jun 36(6)1789-96 Taming Rare Variation With Known Biology in Long QT Syn-drome Perez MV Ashley EA Circ Cardiovasc Genet 2013 Jun 1 6(3)227-9Coronary Microvascular Dysfunction After ST-Segment-Ele-vation Myocardial Infarction Local or Global Phenomenon Yong AS Fearon WF Circ Cardiovasc Interv 2013 Jun 1 6(3)201-3Respiratory-Mode Display of Echocardiographic Images Highlights Effects of Pericardial Disease McConnell MV Wu HH JACC Cardiovasc Imaging 2013 Jun 8 [Epub ahead of print]Risk factors for atrial fibrillation and their population bur-den in postmenopausal women the Womenrsquos Health Ini-tiative Observational Study Perez MV Wang PJ Larson JC Soliman EZ Limacher M Rodriguez B Klein L Manson JE Martin LW Prineas R Connelly S Hlatky M Wassert-heil-Smoller S Stefanick ML Heart 2013 Jun 11 [Epub ahead of print]A Randomized Trial of Exercise Training in Abdominal Aor-tic Aneurysm Disease Myers J McElrath M Jaffe A Smith K Fonda H Hill B Dalman R Med Sci Sports Exerc 2013 Jun 20 [Epub ahead of print]The joint council on thoracic surgery education coronary artery assessment tool has high interrater reliabilityLee R Enter D Lou X Feins RH Hicks GL Gasparri M Takayama H Young JN Calhoon JH Crawford FA Mokadam NA Fann JI Ann Thorac Surg 95(6)2064-70

9

For the complete list of June publications visithttpcvistanfordeduresearchpublicationsjun13pubshtml

CVI PublicationsJuly 96 publications

Raising the pressure on hypertension Reaven G Lancet 2013 Jul 13 382(9887)126-7 Practices and impact of primary outcome adjustment in randomized controlled trials meta-epidemiologic study Saquib N Saquib J Ioannidis JP BMJ 2013 Jul 12 347f431The electrocardiogram at a crossroads Yong CM Froeli-cher V Wagner G Circulation 2013 Jul 2 128(1)79-82The Effect of Tobacco Control Measures during a Period of Rising Cardiovascular Disease Risk in India A Mathematical Model of Myocardial Infarction and Stroke Basu S Glantz S Bitton A Millett C PLoS Med 2013 Jul 10(7)e1001480Prevalence of Anomalous Coronary Arteries in Pulmonary Atresia with Ventricular Septal Defect and Major Aortopulmo-nary Collaterals Muralidaran A Mainwaring RD Reddy VM Hanley FL J Am Coll Cardiol 2013 Jul 3 [Epub ahead of print]Molecular Tension Sensors Report Forces Generated by Sin-gle Integrin Molecules in Living Cells Morimatsu M Mekh-djian AH Adhikari AS Dunn AR Nano Lett 2013 Jul 16 [Epub ahead of print]FK506 activates BMPR2 rescues endothelial dysfunction and reverses pulmonary hypertension Spiekerkoetter E Tian X Cai J Hopper RK Sudheendra D Li CG El-Bizri N Sawada H Haghighat R Chan R Haghighat L de Jesus Perez V Wang L Reddy S Zhao M Bernstein D Solow-Cordero DE Beachy PA Wandless TJ Dijke PT Rabinovitch M J Clin In-vest 2013 Jul 15 [Epub ahead of print]Development of Poly(β-amino ester)-Based Biodegradable Nanoparticles for Nonviral Delivery of Minicircle DNA Kee-ney M Ong SG Padilla A Yao Z Goodman S Wu JC Yang F ACS Nano 2013 Jul 16 [Epub ahead of print]Temperature - The ldquoIgnoredrdquo Factor at the NanoBio Interface Mahmoudi M Abdelmonem AM Behzadi S Clement JH Dutz S Ejtehadi MR Hartmann R Kantner K Linne U Maffre P Metzler S Moghadam M Pfeiffer C Rezaie M Ruiz-Lozano P Serpooshan V Shokrgozar M Nienhaus GU Parak WJ ACS Nano 2013 Jul 10 [Epub ahead of print]

Apoptosis and other immune biomarkers predict influenza vaccine responsiveness Furman D Jojic V Kidd B Shen-Orr S Price J Jarrell J Tse T Huang H Lund P Maecker HT Utz PJ Dekker CL Koller D Davis MM Mol Syst Biol 2013 Jul 2 9680Activatable oligomerizable imaging agents for photoacous-tic imaging of furin-like activity in living subjects Dragules-cu-Andrasi A Kothapalli SR Tikhomirov GA Rao J Gam-bhir SS J Am Chem Soc 2013 Jul 31 135(30)11015-22

Clonal precursor of bone cartilage and hematopoietic niche

stromal cells Chan CK Lindau P Jiang W Chen JY Zhang LF Chen CC Seita J Sahoo D Kim JB Lee A Park S Nag D Gong Y Kulkarni S Luppen CA Theologis AA Wan DC Deboer A Seo EY Vincent-Tompkins JD Loh K Walmsley GG Kraft DL Wu JC Longaker MT Weissman IL Proc Natl Acad Sci USA 2013 Jul 30 110(31)12643-8Reconstituting pancreas development from purified pro-genitor cells reveals genes essential for islet differentiation Sugiyama T Benitez CM Ghodasara A Liu L McLean GW Lee J Blauwkamp TA Nusse R Wright CV Gu G Kim SK Proc Natl Acad Sci USA 2013 Jul 3 110(31)12691-6 Genetic measurement of memory B-cell recall using anti-body repertoire sequencing Vollmers C Sit RV Weinstein JA Dekker CL Quake SR Proc Natl Acad Sci USA 2013 Jul 29 [Epub ahead of print]A small animal Raman instrument for rapid wide-area spectroscopic imaging Bohndiek SE Wagadarikar A Za-valeta CL Van de Sompel D Garai E Jokerst JV Yazdan-far S Gambhir SS Proc Natl Acad Sci USA 2013 Jul 23 110(30)12408-13Disease-Related Growth Factor and Embryonic Signaling Pathways Modulate an Enhancer of TCF21 Expression at the 6q232 Coronary Heart Disease Locus Miller CL Anderson DR Kundu RK Raiesdana A Nuumlrnberg ST Diaz R Cheng K Leeper NJ Chen CH Chang IS Schadt EE Hsiung CA Assimes TL Quertermous T PLoS Genet 2013 Jul 9(7)e1003652Comparison of the response to endovascular reperfusion in relation to site of arterial occlusion Lemmens R Mlynash M Straka M Kemp S Bammer R Marks MP Albers GW Lansberg MG Neurology 2013 Jul 12 [Epub ahead of print]Mendelian Randomisation Studies Do Not Support a Caus-al Role for Reduced Circulating Adiponectin Levels in In-sulin Resistance and Type 2 Diabetes Yaghootkar H Lam-ina C Scott RA [+30 authors] Assimes TL [+4 authors] Knowles JW [+4 authors] Quertermous T [+33 authors] Frayling TM Diabetes 2013 Jul 8 [Epub ahead of print]Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes Kim SH Abbasi F Lamendola C Liu A Ariel D Schaaf P Grove K Tomasso V Ochoa H Liu YV Chen YD Reaven G Diabetes Care 2013 Jul 8 [Epub ahead of print]Hemodynamic regulation of reactive oxygen species Impli-cations for vascular diseases Raaz U Toh R Maegdefessel L Adam M Nakagami F Emrich F Spin JM Tsao PS Antiox-id Redox Signal 2013 Jul 23 [Epub ahead of print]

For the complete list of July publications visithttpcvistanfordeduresearchpublicationsjul13pubshtml

10

Cardiac aging and rejuvenation--a sense of humors Rando TA Finkel T N Engl J Med 2013 Aug 8 369(6)575-6Sequencing Y chromosomes resolves discrepancy in time to common ancestor of males versus females Poznik GD Henn BM Yee MC Sliwerska E Euskirchen GM Lin AA Snyder M Quintana-Murci L Kidd JM Underhill PA Bustamante CD Science 2013 Aug 2 341(6145)562-5Global epigenomic reconfiguration during mammalian brain development Lister R Mukamel EA Nery JR Urich M Puddifoot CA Johnson ND Lucero J Huang Y Dwork AJ Schultz MD Yu M Tonti-Filippini J Heyn H Hu S Wu JC Rao A Esteller M He C Haghighi FG Sejnowski TJ Behrens MM Ecker JR Science 2013 Aug 9 341(6146)

QRS duration bundle-branch block morphology and out-comes among older patients with heart failure receiving car-diac resynchronization therapy Peterson PN Greiner MA Qualls LG Al-Khatib SM Curtis JP Fonarow GC Hammill SC Heidenreich PA Hammill BG Piccini JP Hernandez AF Curtis LH Masoudi FA JAMA 2013 Aug 14 310(6)617-26

Kidney disease and cardiovascular risk whether black or white race matters Weiner DE Winkelmayer WC JAMA 2013 Aug 21 310(7)697-8

Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies Lee AS Tang C Rao MS Weissman IL Wu JCNat Med 2013 Aug 19(8)998-1004

Cost-Effectiveness of Percutaneous Coronary Intervention in Patients with Stable Coronary Disease and Abnormal Frac-tional Flow Reserve Fearon WF Shilane D Pijls NH Boo-throyd DB Tonino PA Barbato E Juni P De Bruyne B Hlat-ky MA on behalf of the FAME 2 Investigators Circulation 2013 Aug 14 [Epub ahead of print]

Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation A Randomized Clinical Trial Katritsis DG Pokushalov E Romanov A Giazitzoglou E Siontis GC Po SS Camm AJ Ioannidis JP J Am Coll Cardi-ol 2013 Aug 8

Molecular Tension Sensors Report Forces Generated by Sin-gle Integrin Molecules in Living Cells Morimatsu M Mekh-djian AH Adhikari AS Dunn AR Nano Lett 2013 Aug 28 [Epub ahead of print]Cortical bone-derived stem cells a novel class of cells for myocardial protection Ong SG Wu JC Circ Res 2013 Aug 16 113(5)480-3 Genome-wide Association Analysis of Blood-Pressure Traits in African-Ancestry Individuals Reveals Common Associated Genes in African and Non-African Populations Franceschi-

ni N Fox E Zhang Z [+ 83 authors] Snyder M the Asian Genetic Epidemiology Network Consortium [+ 18 au-thors] Zhu X Am J Hum Genet 2013 Aug 20 [Epub ahead of print]

Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension Tian W Jiang X Tamosiuniene R Sung YK Qian J Dhillon G Gera L Far-kas L Rabinovitch M Zamanian RT Inayathullah M Fridlib M Rajadas J Peters-Golden M Voelkel NF Nicolls MR Sci Transl Med 2013 Aug 28 5(200)200ra117

US studies may overestimate effect sizes in softer research Fanelli D Ioannidis JP Proc Natl Acad Sci USA 2013 Aug 26 [Epub ahead of print]

The effect of bioengineered acellular collagen patch on car-diac remodeling and ventricular function post myocardial infarction Serpooshan V Zhao M Metzler SA Wei K Shah PB Wang A Mahmoudi M Malkovskiy AV Rajadas J Butte MJ Bernstein D Ruiz-Lozano P Biomaterials 2013 Aug 24 [Epub ahead of print]

Focused transthoracic echocardiography during criti-cal care medicine training curriculum implementation and evaluation of proficiency Beraud AS Rizk NW Pearl RG Liang DH Patterson AJ Crit Care Med 2013 Aug 41(8)e179-81

Changing the Culture of Academic Medicine to Eliminate the Gender Leadership Gap 5050 by 2020 Valantine H Sand-borg CI Acad Med 2013 Aug 21 [Epub ahead of print]

Early acute lung injury criteria for identifying lung injury prior to the need for positive pressure ventilation Levitt JE Calfee CS Goldstein BA Vojnik R Matthay MA Crit Care Med 2013 Aug 41(8)1929-37

Computation of Coding Variants in African Americans Bet-ter Performance using Data from the Exome Sequencing Project Duan Q Liu EY Auer PL [+ 21 authors] Assimes TL [+ 9 authors] Li Y Bioinformatics 2013 Aug 16 [Epub ahead of print]

Integrin-Targeted Molecular Imaging of Experimental Ab-dominal Aortic Aneurysms by 18F-FPPRGD2 Positron Emis-sion Tomography Kitagawa T Kosuge H Chang E James ML Yamamoto T Shen B Chin FT Gambhir SS Dalman RL McConnell MV Circ Cardiovasc Imaging 2013 Aug 30 [Epub ahead of print]

Deletion of the β2-adrenergic receptor prevents the develop-ment of cardiomyopathy in mice Fajardo G Zhao M Urashi-ma T Farahani S Hu DQ Reddy S Bernstein D J Mol Cell Cardiol 2013 Aug 3 63C155-164

CVI PublicationsAugust 90 publications For the complete list of August publications visit

httpcvistanfordeduresearchpublicationsaug13pubshtml

11

SEPTEMBERAmerican Society of TransplantationAST Basic Science and Clinical Sci-ence Fellowship Grants$40000year for up to 2 yearsOpen for applications September 9 2013

Katherine McCormick Advanced Postdoctoral Scholar Fellowships$35000yearSeptember 16 2013

National Institutes of Health Direc-torrsquos Early Independence Award$250000year for 5 yearsInternal Deadline September 30 2013

OCTOBERThe Helena Anna Henzl-Gabor Young Women in Science Postdoc-toral Scholars Travel Fellowship$2000 per awardeeOpen for application October 1 2013

Life Sciences Research FoundationPostdoctoral Fellowship Program$50000 to $60000 for 2 yearsOctober 1 2013

Cystic Fibrosis FoundationClinical Fellowships 1st amp 2nd Year$47600-$49250 for 2 yearsOctober 2 2013

National Institutes of HealthK Career Development AwardsOctober 12 2013

CVI Postdoctoral Fellow Travel Awards$750 per awardeeOctober 15 2013

Thoracic Surgery Foundation For Research and EducationNina Staff Braunwald Research Fellowship$30000 year up to 2 yearsOctober 15 2013

NOVEMBERAP Giannini Family FoundationMedical Fellowship Program$136000 over 3 yearsNovember 4 2013

Stanford Prevention Research CenterSPRC Research Fellowship Program in Cardiovascular Disease PreventionNovember 15 2013

DECEMBERAmerican Federation for Aging ResearchEllison Medical Foundation AFAR Postdoctoral Fellows in Aging Re-search Program$47114 to $55670 for 1 yearLOI December 16 2013

Upcoming GrantsSEPTEMBER

Foundation LeduqTransatlantic Networks of Excellence$6 million over 5 yearsLOI September 15 2013

American College of CardiologyACCFMerck Research Fellowships in Cardiovascular Disease and Cardiometabolic Disorders$70000yearSeptember 23 2013

ACCFWilliam F Keating Esq Endow-

ment Career Development Award $70000yearSeptember 23 2013

ISCTR-ACCF Cardiovascular Trans-lational Research Scholarship$60000yearSeptember 23 2013

OCTOBERACCF Young Investigator Awards Competition$2000 + $1500 travel costsOctober 4 2013

NIH Directorrsquos New Innovator

Award Program $300000year for 5 yearsOctober 25 2013

Ellison Medical FoundationNew Scholar Program in Aging Award$100000year for 4 yearsOctober 2013 by invitation

DECEMBERMDA Research Grants amp Develop-ment Grants$60000yearLOI December 15 2013

Postdoctoral amp Pre-doctoral Awards

12

ldquoCardiovascular Diseaserdquo is now on the left hand navigation table in the Research Management Grouprsquos (RMG) Funding Infor-mation Resource webpage This webpage provides links to recent announcements internal Stanford funding opportunities NIH NSF foundations postdoctoral fellowships graduate student funding opportunities as well as to a searchable funding database Visit this great resource at httpmedstanfordedurmgfunding

To be added to funding opportunity email distribution lists please contact Jeanne Heschele at RMG at jheschelestanfordedu

CVI Frontiers Seminars

SEPTEMBER

The Familial Hypercholesterolemia Summit Awareness to ActionSeptember 19 2013 Annapolis MD

Western Vascular SocietySeptember 21-24 2013Jasper AB Canada

Heart Failure Society of America 17th Annual Scientific MeetingSeptember 22-25 2013 Orlando FL

NHLBI Symposium on Cardiovascu-lar Regenerative MedicineSeptember 25-26 2013 Bethesda MD

OCTOBER

Women at the Heart of Leadership 2013 Women in Medicine and Sci-ence ConferenceOctober 12 2013Stanford CA

Vascular Biology 2013 ndash North

13

Upcoming Meetings

Li Ka Shing Center for Learning amp Knowledge 291 Campus Drive Stanford CA 94305 Keynote SpeakerShaun R Coughlin MD PhDDirector Cardiovascular Research Institute UCSF

SAVE THE

DATESEPTEMBER

12 amp 132013

Shaun Coughlin

CVI Annual RetreatPhoto Linda A Cicero Stanford News Servic

e

8202013Michael S Lauer MD NIHNHLBI -- Director Division of Cardiovascular Sci-ences National Heart Lung and Blood Institute

9242013Aaron Gitler PhD Associate Profesor Dept of Genetics Stanford

1012013 Gerald Dorn MD Philip amp Sima K Needleman Professor of Medicine Washington University in St Louis MO

1082013Neil Ingels PhD Consulting Professor Cardiothoracic Surgery - Adult Cardiac Surgery Stanford

10222013 Alan Daugherty PhD Editor ATVBSenior Assoc Dean of Research Unversi-ty of Kentucky

10292013 Philip Sager MD CVI Consulting Pro-fessor Stanford

1152013Mark E Anderson MD PhD Profes-sor of Medicine and Physiology Head Department of Internal Medicine Direc-tor University of Iowa Cardiovascular Research Center

11122013 Bernard J Gersh MB ChB Dphil Professor of Medicine Cardiovascular Diseases Mayo Clinic

11262013Luiz Berlardinni MD Senior Vice President of Cardiovascular Therapeutics at Gilead Sciences Inc

Register Here

American Vascular Biology Organi-zation (NAVBO)October 20-24 2013Hyannis MA

NOVEMBER

AHA Scientific Sessions 2013November 16-20 2013Dallas TX

Vascular Endovascular Issues Tech-niques Horizons (VEITH)November 19-23 2013New York NY

12 noon to 1 pm Tuesdays Li Ka Shing Center Stanford School of Medicine 291 Campus Drive Stanford

14

Tom Quertermous Alan Yeung

Ronald Dalman Philip OyerDominik Fleischmann

Robert Harrington

Cardiovascular Institute LeadershipJoseph C Wu MD PhDDirector Stanford Cardiovascular Institute Professor Dept of Medicine (Cardiology) and Radiology

Joseph Wu

Kenneth Mahaffey

Stephen Roth

Mark Nicolls

Michael Snyder

Robert A Harrington MDArthur L Bloomfield Professor of Medicine

Chair Dept of MedicineDirector of Clinical Investigations Cardiovascular Institute

Marlene Rabinovitch

Ronald L Dalman MDWalter C and Elsa R Chidester Professor of SurgeryChief Division of Vascular Surgery

Dominik Fleischmann MDProfessor Dept of RadiologyChief Cardiovascular Imaging

Kenneth Mahaffey MDProfessor Dept of MedicineVice Chair of Medicine for Clinical Research

Mark Nicolls MDAssociate Professor Dept of Medicine (Pulmonary and Critical Care Immunology and Rheumatology)Chief Pulmonary and Critical Care Medicine

Philip E Oyer MD PhDRoy B Cohn-Theodore A Falasco Professor inCardiothoracic SurgeryInterim Chair Dept of Cardiothoracic Surgery

Tom Quertermous MDWilliam G Irwin Professor of MedicineCo-Chief (Research) Division of Cardiovascular MedicineMarlene Rabinovitch MDDwight and Vera Dunlevie Professor in PediatricCardiology

Stephen J Roth MD MPHProfessor and Chief Pediatric CardiologyDirector Childrenrsquos Heart Center

Michael Snyder PhDProfessor and Chair Dept of GeneticsDirector Stanford Center for Genomics and Personalized Medicine

Alan Yeung MDLi Ka Shing Professor of MedicineCo-Chief (Clinical) Division of CardiovascularMedicine